| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 55390-0453-01 | 55390-0453 | Mitomycin | Mitomycin | Chemotherapy | Antitumor Antibiotic | Alkylating Agent/ Mitomycin | Intravenous | Oct 11, 2001 | Oct 31, 2012 | No Longer Used | |
| 00069-9144-11 | 00069-9144 | Docetaxel | Docetaxel | 200.0 mg/20mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Jun 23, 2014 | Apr 30, 2017 | No Longer Used |
| 68382-0244-16 | 68382-0244 | Imatinib mesylate | Imatinib mesylate | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Jan 21, 2021 | In Use | |
| 40051-0609-12 | 40051-0609 | Temozolomide | Temozolomide | 250.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Aug 1, 2016 | In Use | |
| 68001-0551-41 | 68001-0551 | Pemetrexed disodium | Pemetrexed | 500.0 mg/20mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | Sep 7, 2022 | In Use | |
| 47335-0930-74 | 47335-0930 | Temozolomide | Temozolomide | 180.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Feb 13, 2014 | In Use | |
| 00078-1098-30 | 00078-1098 | asciminib | SCEMBLIX | 40.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | ABL/BCR-ABL1 | Oral | Oct 29, 2021 | In Use | |
| 00075-8005-01 | 00075-8005 | Docetaxel | Taxotere | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | May 4, 2012 | Dec 23, 2013 | No Longer Used | |
| 65162-0794-03 | 65162-0794 | Imatinib | Imatinib Mesylate | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Feb 8, 2019 | In Use | |
| 40051-0604-51 | 40051-0604 | Temozolomide | Temozolomide | 5.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Aug 1, 2016 | In Use | |
| 00069-0136-01 | 00069-0136 | Bosutinib monohydrate, Bosutinib | Bosulif | 500.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Sep 4, 2012 | In Use | |
| 57277-0106-15 | 57277-0106 | carboplatin Injection | Carboplatin | 150.0 mg/5mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Sep 29, 2016 | In Use | |
| 73116-0215-28 | 73116-0215 | Duvelisib | COPIKTRA | 15.0 mg/1 | Chemotherapy | Enzyme Inhibitor | PI3K | Oral | Sep 25, 2018 | In Use | |
| 51407-0749-05 | 51407-0749 | Cyclophosphamide | CYCLOPHOSPHAMIDE | 200.0 mg/mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous | Mar 20, 2023 | Apr 30, 2025 | No Longer Used |
| 81927-0105-01 | 81927-0105 | Thiotepa | TEPYLUTE | 10.0 mg/mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard /Ethylenimine | Intravenous | Mar 31, 2025 | In Use | |
| 62856-0724-30 | 62856-0724 | Lenvatinib | Lenvima | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FGF, PDGFR, KIT, RET | Oral | Feb 13, 2015 | In Use | ||
| 63759-3001-01 | 63759-3001 | Capecitabine | Capecitabine | 500.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | Dec 31, 2016 | In Use | |
| 64842-0120-05 | 64842-0120 | FUTIBATINIB | LYTGOBI | 4.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | FGFR | Oral | Feb 3, 2023 | In Use | |
| 00310-0679-60 | 00310-0679 | Olaparib | Lynparza | 150.0 mg/1 | Chemotherapy | Enzyme Inhibitor | PARP | Oral | Aug 17, 2017 | In Use | |
| 16729-0114-11 | 16729-0114 | Etoposide | Etoposide | 20.0 mg/mL | Chemotherapy | Plant Alkaloid | Epipodophyllotoxins | Intravenous | Mar 3, 2015 | In Use | |
| 70121-1483-07 | 70121-1483 | Arsenic Trioxide | Arsenic Trioxide | 1.0 mg/mL | Chemotherapy | Miscellaneous Agent | PML/RARa | Intravenous | Jan 25, 2021 | In Use | |
| 68001-0282-26 | 68001-0282 | Gemcitabine Hydrochloride | Gemcitabine Hydrochloride | 38.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | May 23, 2016 | Aug 1, 2021 | No Longer Used |
| 50419-0397-01 | 50419-0397 | SEVABERTINIB | HYRNUO | 10.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | HER2, EGFR | Oral | Nov 19, 2025 | In Use | |
| 63850-0130-02 | 63850-0130 | Everolimus | Everolimus | 5.0 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Jan 30, 2025 | In Use | |
| 00143-9219-01 | 00143-9219 | Idarubicin Hydrochloride | Idarubicin Hydrochloride | 1.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Jan 30, 2017 | In Use |
Found 12159 results — Export these results
Home